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NICE has accredited the process used by the British Association of
Dermatologists to produce clinical guidelines. The renewed accredita-
tion is valid until 31 May 2021 and applies to guidance produced
using the process described in the updated guidance for writing a
British Association of Dermatologists clinical guidance – the adop-
tion of the GRADE methodology 2016. The original accreditation
term began on 12 May 2010. More information on accreditation
can be viewed at www.nice.org.uk/accreditation.
1.0 Purpose and scope
The overall objective of the guidelines is to provide up-to-
date, evidence-based recommendations on the investigation
and management of secondary pruritus without underlying
skin disorder and generalized pruritus of unknown origin
(GPUO) in adults (excluding children aged < 18 years). The
document aims to: (i) offer an appraisal of all relevant lit-
erature up to November 2016, focusing on any key devel-
opments; (ii) address important, practical clinical questions
relating to the primary guidelines objective (i.e. accurate
diagnosis and identification of cases and suitable treatment);
(iii) provide guideline recommendations; (iv) where appro-
priate, provide practical and health economic implications;
and (v) discuss potential developments and future direc-
tions.
The guidelines are presented as a detailed review with high-
lighted recommendations for practical use in the clinic (see
section 13), in addition to an updated patient information
leaflet [available on the British Association of Dermatologists
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(BAD) website, http://www.bad.org.uk/for-the-public/
patient-information-leaflets].
1.1 Exclusions
These guidelines do not cover primary dermatological pruritic
conditions, localized pruritus or pruritus in children.1 Also, the
management of pruritus associated with pregnancy is not cov-
ered, as there has been a recent Cochrane review of this topic.2
2.0 Stakeholder involvement and peer review
The Guidelines Development Group (GDG) consisted of clini-
cians from dermatology, nursing, primary care, oncology,
nephrology, hepatology and haematology. The draft document
was circulated to the BAD membership, the British Dermatologi-
cal Nursing Group and the Primary Care Dermatological Society
for comments, which were considered by the GDG, and peer
reviewed by the Clinical Standards Unit of the BAD (made up of
the Therapy & Guidelines subcommittee) prior to publication.
3.0 Methodology
This set of guidelines has been developed using the BAD rec-
ommended methodology3 and with reference to the Appraisal
of Guidelines Research and Evaluation (AGREE II) instrument
(www.agreetrust.org).4 Recommendations were developed for
implementation in the National Health Service using a process
of considered judgement based on the evidence. Targeted liter-
ature searches were carried out in the PubMed, MEDLINE and
Embase databases for meta-analyses, randomized and nonran-
domized controlled clinical trials, case series, case reports and
open studies involving treatments for pruritus published in the
English language up to November 2016. The search terms and
strategies are detailed in Appendix S1 (see Supporting Informa-
tion). Additional relevant references were identified from cita-
tions in the reviewed literature. All identified titles were
screened and those relevant for first-round inclusion were
selected for further scrutiny. The abstracts for the shortlisted
references were then reviewed by the GDG and the full papers
of relevant material obtained; disagreements in the final selec-
tions were resolved by discussion with the entire GDG. The
structure of the guidelines was then discussed, with headings
and subheadings decided; different coauthors were allocated
separate subsections. Each coauthor then performed a detailed
appraisal of the selected literature with discussions within the
GDG to resolve any issues. All subsections were subsequently
collated and edited to produce the final set of guidelines.
4.0 Limitations of the guidelines
This document has been prepared on behalf of the BAD and is
based on the best data available when the document was pre-
pared. It is recognized that under certain conditions it may be
necessary to deviate from the guidelines and that the results of
future studies may require some of the recommendations
herein to be changed. Failure to adhere to these guidelines
should not necessarily be considered negligent, nor should
adherence to these recommendations constitute a defence
against a claim of negligence. Limiting the review to English-
language references was a pragmatic decision but the authors
recognize this may exclude some important information pub-
lished in other languages. For example, certain papers cited in
the European guidelines on chronic pruritus, published in
2012, are not written in English.5
5.0 Plans for guideline revision
The proposed revision for this set of recommendations is
scheduled for 2023; where necessary, important interim
changes will be updated on the BAD website.
6.0 Introduction
Pruritus (itch) is a common and distressing symptom of many
dermatological, systemic and psychological disorders
(Table 1). It is perhaps the most common presenting symp-
tom in dermatology (Table 2).6,7 The focus of these guideli-
nes is the investigation and management of both
noncutaneous secondary causes of pruritus due to an underly-
ing disorder, and GPUO, which forms about 8% of all cases
of pruritus.8 There is a significantly impaired quality of life
associated with itch, similar to that of chronic pain.5,9,10
Pruritus can be defined as ‘the sensation that is relieved by
scratching the skin’.6,7 Somatosensory neurones carry the
sense of touch, as well as pain and itch.11 Any tissue damage
or inflammation can produce either localized or generalized
pruritus.11 Both pain and itch sensations arise by activation of
primary sensory neurones, but there is experimental evidence
that these two sensations are transduced by distinct subpopula-
tions of sensory neurones and spinal afferent pathways,
although there may be ‘cross-talk’ between these two distinct
neuronal circuits.11 Various centres within the central nervous
system have been implicated in the perception of chronic pru-
ritus, including signal transducer and activator of transcription
3- and lipocalin-2-mediated signalling in astrocytes,12 c-ami-
nobutyric acid (GABA)A receptor activation in the central
nucleus of the amygdala,13 and signalling in the middle supe-
rior temporal gyrus and right inferior frontal gyrus/insula.14
Itch is a common symptom in the general population, with
a 2-week-period prevalence of acute itch of 84%.10 The
Table 1 Basic classification of pruritus
1. Pruritus with associated underlying dermatosis
2. Pruritus with no underlying dermatosis
2a. Secondary pruritus due to underlying systemic
disorder (secondary pruritus)
2b. Generalized pruritus of unknown origin (GPUO)
Note that type 2a and 2b pruritus may have secondary changes
due to rubbing or excoriation
Acute: < 6 weeks; chronic: > 6 weeks
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pathophysiology of itch is the subject of a number of reviews
to which the reader is referred6,7,11 and is beyond the scope
of these guidelines.
Itch may be acute (< 6 weeks) or chronic (> 6 weeks).
Chronic itch has a prevalence of approximately 17% in
adults;15 however, this may be much higher in the elderly
(> 65 years), where the figure is likely to be 50% or
higher.16 The quality of perception of itch may be sex depen-
dent.17
The management of pruritus requires a detailed history and
examination coupled with appropriate investigations, directed
from the initial clinical assessment. A major aim of these
guidelines is to evaluate screening investigations in generalized
pruritus without cutaneous signs and their value in the
absence of clinical evidence of systemic disease such as blood
disorders, renal disease, liver disease or malignancy.
It is difficult to assess the intensity, severity and course of
pruritus accurately. It is also hard to characterize and define
the sensation. Tools have been developed and validated for
baseline assessment and evaluation of treatment efficacy of
pruritus, thus allowing comparison between clinical studies.
Commonly used tools for self-reporting of pruritus intensity
are the visual analogue scale (VAS), numerical rating scale and
verbal rating scale.18 The use of a patient-completed 10-cm
VAS and perhaps the Dermatology Life Quality Index19 is rec-
ommended to provide a baseline measure of itch activity to
help quantify management outcomes. However, as yet, there
is no international consensus on how to measure the severity
of itch.20 Moreover, there may be differences in how patients
and physicians assess the severity of pruritus.21–23
The management of pruritus depends on the treatment of
any underlying disease. Symptomatic measures may be appro-
priate in patients where no cause can be identified or treated.
More directed management can be divided into topical treat-
ments, systemic treatments, phototherapy, psychological
approaches or alternative therapies.5,24 Palliative care is a spe-
cialized situation and, in general, the therapy of the pruritus
should be centred on the individual circumstances of the
patient.25
7.0 Investigation of generalized pruritus
without rash and interventions for secondary
generalized pruritus
7.1 Iron deficiency and pruritus
In all cases of generalized pruritus without rash (GPWOR), but
especially where iron loss is suspected, it is important to enquire
about diet (vegetarian or vegan), potential sources of blood loss
and gastrointestinal symptoms. Generalized pruritus associated
with iron deficiency was first described over 40 years ago.26–29
Iron replacement leads in some cases to complete cessation of
pruritus very shortly after commencement of therapy.26,28
A prospective case–control study showed that the mean serum
iron levels in the population of patients with pruritus was signif-
icantly lower than that in the control group, with no median age
difference between the two groups. Furthermore, the most com-
mon cause of generalized pruritus in patients with underlying
systemic disease was found to be iron deficiency anaemia, which
responded to iron replacement (25% of all patients with pruritus
with systemic disease).30 Therefore, we recommend that full
blood count and ferritin levels should be checked in all patients
with chronic GPWOR. Note that ferritin is an acute-phase pro-
tein and may be elevated in a situation of iron deficiency.
Where iron deficiency is suspected, and ferritin is appar-
ently ‘normal’, it may be necessary to check serum iron and
total iron binding capacity as well. A trial of iron replacement
should be given if the ferritin is below the lower limit of the
reference range (between 15 and 25 lg L1 in most U.K. lab-
oratories) or if there is anaemia or microcytosis not attributa-
ble to any other cause (e.g. gastrointestinal blood loss, loss in
the urine, thalassaemia trait or polycythaemia). Those who
have unexplained iron deficiency should also be tested for tis-
sue transglutaminase (TTG) antibodies. This is assuming they
have not been excluding gluten for at least 6 weeks. If this is
abnormal, they should be referred to a gastroenterologist for
consideration of endoscopy and small bowel biopsy. A biopsy
may be indicated anyway, even with a negative TTG.31 IgA
deficiency is relatively common in the population and, if pre-
sent, TTG measurement may give a falsely negative reading.
Recommendation
• Full blood count and ferritin levels should be checked
in all patients with chronic GPWOR (Strength of recommen-
dation C; Level of evidence 2++) (see Appendix)
7.2 Iron overload
Iron overload may also be associated with generalized pruri-
tus, either in association with haemochromatosis32–34 or with
hyperferritinaemia in the absence of haemochromatosis.35
Important confounding variables are that iron overload is asso-
ciated with both liver infiltration35 (see section 7.7) and
Table 2 Causes of generalized pruritus without rash
Pruritic skin diseases before rash
Disorders of iron metabolism
Uraemia
Hepatic disease (especially cholestasis)
Malignancy
Haematological disorders
Infection
Endocrine disease
Neurological disorders
Psychological and emotional factors
Adverse drug reactions
Heart failure
Pregnancy
Pruritus of elderly skin
Pruritus of unknown origin (GPUO)
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diabetes mellitus (see section 7.5).32–34 Treatment of iron
overload by venesection in such cases can reduce or remove
the sensation of pruritus.32–35
Recommendation
• Liver functions tests should be considered for patients
with generalized pruritus associated with iron overload
(Strength of recommendation D; Level of evidence 3)
7.3 Haematological causes of pruritus
GPWOR can be the presenting symptom of essential poly-
cythaemia vera (PV) and secondary polycythaemia, due to lung or
kidney disease.36 It is also associated with Hodgkin lymphoma,37
but is unusual in other types of lymphoma, such as non-Hodgkin
lymphoma (NHL). Myeloma presents with GPWOR extremely
rarely.38 It is also linked with sickle cell disease, but this is proba-
bly due to opiates (see section 7.11), which are commonly used
to treat pain in this disorder.39 Haematological causes of GPWOR
account for approximately 2% of the total.40
Evidence of an underlying haematological disorder may be
identified from the history and examination. Aquagenic pruri-
tus is characterized by the development of intense itching,
without the development of skin lesions, evoked by contact
with water. It is characteristic of PV,36 although there are
other causes. Itching at night in association with weight loss,
fevers and night sweats is suggestive of lymphoma.37 Any
enlarged lymph nodes or masses should be referred for exci-
sion or ultrasound-assisted core biopsy.41
A skin biopsy may very occasionally be necessary in persis-
tent, unexplained pruritus, as patients may very rarely present
with pruritus and normal-looking skin, who subsequently prove
to have skin lymphoma on biopsy, usually taken from the
trunk.42–44
Initial investigation of patients with pruritus, where
haematological involvement is suspected, should include full
blood count, blood film, erythrocyte sedimentation rate (ESR,
if available) and lactate dehydrogenase.45 PV should be con-
sidered in the presence of a raised haemoglobin or haemat-
ocrit, especially in association with microcytosis (suggesting
secondary iron deficiency), raised white cell or platelet count
and low ESR. If PV is suspected, blood should be analysed
for the Janus kinase (JAK)2 V617F mutation, which is pre-
sent in up to 97% of cases.46 In the absence of the JAK2
mutation, secondary causes of polycythaemia should be
investigated where possible by means of clinical assessment,
renal and liver function tests, serum erythropoietin level,
measurement of oxygen saturation, chest X-ray and abdomi-
nal ultrasound.47 A recent randomized controlled trial (RCT)
showed that ruxolitinib (an antibody against JAK1/JAK2) was
very effective at treating PV, producing rapid reductions in
pruritus scores.48
Curative treatment of lymphoma invariably resolves the
associated pruritus.7 However, symptomatic management may
be required while the patient is receiving definitive treatment
or if the lymphoma is incurable. Cimetidine controlled the
pruritus in a series of four patients with Hodgkin lym-
phoma.49 Small case series and case reports have reported suc-
cess with the use of carbamazepine,50 mirtazapine51 and
phototherapy.52 High-dose oral corticosteroids are frequently
used in the treatment and palliation of patients with
lymphoma, and can also provide symptomatic relief from
itching.53
The pruritus associated with PV can persist despite normal-
ization of blood counts with venesection or cytoreductive
therapy.36 Aspirin 300 mg daily has been shown to be effec-
tive in relieving pruritus in a number of patients with PV.54,55
There is evidence from case reports that pruritus associated
with PV may be helped by sodium bicarbonate baths.56 How-
ever, this has not been confirmed in all cases.
Interferon alpha therapy may also be useful.57 It has the
added advantage of being a cytoreductive therapy and there-
fore a treatment for PV, but is poorly tolerated due to myal-
gia, arthralgia, nausea and diarrhoea. Other agents for which
the evidence is limited to case series or reports are selective
serotonin reuptake inhibitors (SSRIs),58 psoralen–ultraviolet A
(PUVA) or ultraviolet (UV)B phototherapy,59,60 cimetidine61
and atenolol.62
In summary, haematological conditions should be consid-
ered in the initial work-up of a patient with pruritus. The evi-
dence for the treatments used in pruritus associated with
haematological conditions is primarily from case reports and
case series.
Recommendations (investigation)
• Patients with generalized pruritus with suspicion of
haematological involvement should have initial investi-
gations including full blood count, blood film, lactate
dehydrogenase and ESR (if available). Immunoglobu-
lins and urinary paraproteins may also be requested,
but will have a low yield, as myeloma is rarely associ-
ated with GPWOR (Strength of recommendation D; Level of evi-
dence 3)
• Patients with generalized pruritus associated with either
PV or suspected Hodgkin lymphoma should be
referred to haematology (Strength of recommendation D; Level
of evidence 4)
• Patients with generalized pruritus with suspicion of PV
(raised haemoglobin or haematocrit) should have
blood samples sent for JAK2 V617F mutation analysis
and/or be referred to haematology (Strength of recommen-
dation D; Level of evidence 4)
• In the absence of JAK2 mutation, secondary causes of
PV should be investigated by means of clinical assess-
ment, renal and liver function tests, serum erythropoi-
etin level, measurement of oxygen saturation, chest X-
ray and abdominal ultrasound (Strength of recommendation
D; Level of evidence 4)
© 2017 British Association of Dermatologists British Journal of Dermatology (2018) 178, pp34–60
BAD guidelines for generalized pruritus, 2018, G.W.M. Millington et al. 37
Recommendations (treatment)
• Patients with generalized pruritus associated with lym-
phoma may have their itch resolved by treatment with
cimetidine, gabapentin, carbamazepine, mirtazapine or
phototherapy (Strength of recommendation D; Level of evidence 3)
• Patients with generalized pruritus associated with
incurable lymphoma may have their itch relieved with
oral corticosteroids (Strength of recommendation D; Level of
evidence 4)
• Patients with generalized pruritus associated with PV
may have their itch relieved with cytoreductive ther-
apy, aspirin, interferon-a, SSRIs, PUVA, UVB pho-
totherapy, cimetidine or atenolol (Strength of
recommendation D; Level of evidence 3)
7.4 Pruritus associated with malignant solid tumours
Solid malignant tumours are a relatively rare cause of pruritus,
and the true prevalence of itch in malignancy is not known.63
Generalized pruritus in malignancy can be multifactorial. It
can be a true paraneoplastic symptom, a feature of paraneo-
plastic dermatoses, secondary to paraneoplastic neuropathy, a
consequence of secondary skin involvement by cutaneous or
noncutaneous primary tumours or a side-effect of cancer treat-
ment (Table 3). Melanomatosis and skin infiltration by
tumours can also cause itching.63–66
When generalized paraneoplastic pruritus is suspected, inves-
tigations should be guided by a thorough history and physical
examination. Features in the history of a patient with chronic
unexplained pruritus that favour a possibility of underlying
malignancy include older age, male sex, possible liver disease
and chronic tobacco usage.67 Generalized pruritus has been
described in breast, colon, lung, testicular and stomach cancers;
insulinoma; gastric carcinoid and thymoma.63,68,69
Although GPWOR can be an initial manifestation of cancer
prior to clinically detectable disease, a full investigation to rule
out malignancy is not necessarily beneficial to patients or cost-
effective, and is therefore not routinely recommended.70,71 A 5-
year cohort study found that GPWOR statistically correlated
with an increased risk of later haematological malignancies or
cholangiocarcinoma, but not other cancers.72 This finding was
complemented by a cohort that recently found that the risk of
manifesting any malignancy was significantly higher in the first
3 months after developing itch.73 Pruritus with systemic symp-
toms of malignancy needs tailored investigations to rule out
specific malignancies. Thus, in those with persistent sudden
onset of severe pruritus, in the absence of any obvious trigger
or other symptoms or signs or abnormal basic investigations, it
may be appropriate to consider a computed tomography scan of
the neck, chest, abdomen and pelvis.
A number of cancer treatments, including radiotherapy, can
lead to pruritus by a variety of mechanisms.63–65 Treatment of
the malignancy can often help to resolve pruritus.63,65,74 Can-
cer-drug-induced pruritus requires modification or discontinua-
tion of medications.63,64 Biological therapies are now
commonly used in oncology. A recent meta-analysis of 33 RCTs
concluded that pruritus was a significant side-effect of cancer
treatment with this class of agent.75 Pruritus is a common side-
effect of epidermal growth factor inhibitors, which have either
biological or intracellular mechanisms of action.76 Oncology
patients receiving biological therapies should be asked about
pruritus on review.
Table 3 Clinical features of cancers associated with generalized pruritus without rash
Pruritus-associated cancers Symptoms Signs
Any (including
haematological)
Loss of appetite, lethargy Weight loss, lymphadenopathy, fever
Breast cancer Breast or axillary lump, change in breast shape,
bloodstained nipple discharge
Breast or axillary lump, change in breast shape,
bloodstained nipple discharge
Colorectal cancer A persistent change in bowel habit, diarrhoea,
abdominal pain, discomfort or bloating
brought on by eating
Blood in the motions, in the absence of haemorrhoids
on examination
Lung cancer Persistent cough and breathlessness, persistent
chest or shoulder pain
Persistent chest infections and wheeze, facial swelling,
hoarse voice, finger clubbing
Gastric cancer Persistent nausea, reflux symptoms, dysphagia
or vomiting
Melaena, jaundice
Cholangiocarcinoma Nonspecific upper abdominal discomfort Jaundice, pale stools, dark urine
Testicular cancer Intermittent dull ache or sharp pain in the
testicle or scrotum
Clinical difference between one testicle and the other
in texture or firmness
Thymoma Persistent cough, shortness of breath, pain or
pressure in the chest, diplopia, dysphagia
Anaemia, frequent infections, muscle weakness, ptosis,
arm or facial swelling
Insulinoma Intermittent double vision or blurred vision,
confusion, anxiety and irritability, dizziness,
mood swings, weakness, sweating and hunger
Symptoms correlate with episodic hypoglycaemia
Gastric carcinoid tumour Abdominal pain, diarrhoea, intermittent facial
flushing
Very rarely, cardiac valve murmurs, cutaneous stigmata
of neurofibromatosis type 1 or tuberous sclerosis
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Antihistamines are generally ineffective in pruritus due to
solid tumours.63–65
Paroxetine 20 mg daily, a serotonin reuptake inhibitor (as
shown in an RCT), and mirtazapine 15–30 mg daily, a 5-hydro-
xytryptamine (5-HT)2 and 5-HT3 antagonist (as shown in a case
series), may have a role in the management of malignant pruri-
tus.51,77 These medicines are thought to act centrally and may
take up to 2–3 weeks to become clinically beneficial.78
Granisetron, a 5-HT3 receptor antagonist, has been used in
a case of pruritus in advanced malignancy, where a continu-
ous infusion (3 mg per 24 h) resulted in prompt reduction in
pruritus in 2 h.79
Aprepitant (a neurokinin-1 receptor antagonist) has been
used in malignancy/cancer treatment-associated pruritus,
including that secondary to biological agents, although there
have been no RCTs, only case reports (125 mg initial dose,
then 80 mg daily dosage).80,81
The management of cancer-related pruritus in a palliative-
care situation may involve use of medicines, such as thalido-
mide, that would not necessarily be chosen in the conven-
tional oncology setting, because of the side-effect profile.82
Recommendations (investigation)
• If paraneoplastic pruritus is suspected, investigations
should be guided by a thorough, regular history and
physical examination, although a full investigation to
rule out malignancy is not routinely recommended
(Strength of recommendation D; Level of evidence 3)
• Pruritus with systemic symptoms of malignancy needs
tailored investigations to rule out specific cancers
(Strength of recommendation D (GPP); Level of evidence 4)
• Oncology patients receiving biological and other thera-
pies should be asked about pruritus on review (Strength
of recommendation A; Level of evidence 1+)
Recommendations (treatment)
• Paraneoplastic pruritus may be relieved with parox-
etine, mirtazapine, granisetron or aprepitant (Strength of
recommendation D; Level of evidence 3)
• The management of paraneoplastic pruritus in the pal-
liative care setting may include a wider range of thera-
pies, such as thalidomide (Strength of recommendation D;
Level of evidence 3)
7.5 Endocrine causes of generalized pruritus
Conventional reviews and medical textbooks state that both
hyperthyroidism and hypothyroidism are associated with gen-
eralized pruritus.83,84 There is limited evidence of this in clini-
cal experimental studies. In a prospective study comparing 55
patients with pruritus and 41 age- and sex-matched controls,
12 patients had a systemic cause of pruritus.30 One of these
12 was hypothyroid and the pruritus responded to thyroxine
replacement.30 Haemoglobin, iron and vitamin B12 levels
were significantly lower in the pruritus group. Thyroid func-
tion tests (TFTs) were not different between the two groups.30
A larger study examined 220 newly diagnosed patients with
thyroid disease and 90 healthy controls for the presence of
skin disease. Chronic nonspecific pruritus, urticaria and vitiligo
were all significantly more common in those diagnosed with
thyroid disease, but pruritus was not a common finding in the
thyroid group (27%).85 Another retrospective study, follow-
ing up 263 patients with pruritus for 3 years, found only
three instances of associated thyroid disease.86 If thyroid dis-
ease is causative in pruritus, it is uncommon.
Some textbooks and reviews state that primary hypoparathy-
roidism may be associated with pruritus, particularly if there are
cutaneous calcium deposits,87 but this is not borne out by larger
studies.30,86 Early case reports suggested that subtotal parathy-
roidectomy for secondary hyperparathyroidism of renal failure
improved uraemic pruritus,88,89 and a larger case series sup-
ported this observation.90 However, in a study of 50 uraemic
patients receiving haemodialysis, levels of parathyroid hormone
(PTH), calcium, phosphate, calcium phosphate product or serum
phosphorus were found not to correlate with pruritus.91 Cinacal-
cet hydrochloride binds to calcium-sensing receptors in the
parathyroid gland to treat secondary hyperparathyroidism.92 It
may be useful in treating the pruritus of secondary hyperparathy-
roidism.92 However, vitamin D may alleviate pruritus in uraemic
patients undergoing either peritoneal dialysis or haemodialysis;
it should be noted that in that study it is not clear whether the
patients were vitamin D deficient, nor is the replacement dose
specified.93
Reducing the phosphate levels in patients with uraemic pru-
ritus might also reduce pruritus, as shown in one cross-sec-
tional study.94 In a descriptive case series including patients
with GPWOR, as well as pruritic dermatoses, 90% were found
to be vitamin D deficient. These often benefited from oral sup-
plementation with vitamin D, at a dose of 50 000 IU weekly
for 8–12 weeks.95 In conclusion, the evidence regarding cal-
cium metabolism and its effects on pruritus is not clear,
although some may benefit from vitamin D supplementation.
Other endocrine conditions that may occasionally be linked
with nonspecific pruritus include diabetes mellitus,30,86 obe-
sity86 and insulinoma96 (Level of evidence 3.) Recently, diabetic
neuropathy has been associated with pruritus affecting pre-
dominantly the trunk.97 Diabetes and obesity are such com-
mon problems that it may be difficult to make any significant
epidemiological link with pruritus, which is also common.86
In summary, there is little evidence to support routine
endocrine investigations (including TFTs) in the investigation
of nonspecific, generalized pruritus, in the absence of any
supporting clinical features suggesting diabetes, endocrinopa-
thy or renal disease.
Recommendations (investigation)
• Patients with generalized pruritus should not undergo
routine endocrine investigations (including TFTs)
unless they present with additional clinical features
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suggesting diabetes, other endocrinopathy or renal dis-
ease (Strength of recommendation D; Level of evidence 3)
• Vitamin D supplementation may help some people
affected by GPWOR (Strength of recommendation D; Level of
evidence 3)
7.6 Uraemic pruritus
Pruritus is a common feature of patients with end-stage renal
disease (ESRD) or chronic kidney disease.98–100 The symptoms
vary from mild intermittent irritation to intractable itch associ-
ated with very poor sleep and diminished quality of life. In two-
thirds of patients, the pruritus is generalized, while in others it
affects mainly the back, face or arteriovenous fistula arm. Urae-
mia causes severe episodes of pruritus, especially during the
summer or at night. Although pruritus sometimes improves at
the start of dialysis,101 some patients experience itch, during or
soon after treatment, usually beginning within 6 months of the
onset of dialysis.98–100 In the Dialysis Outcomes and Practice
Patterns Study of over 1800 patients, the incidence of pruritus
in patients on haemodialysis was 42%.99 Overall, the severity of
pruritus is lower in ESRD treated with peritoneal dialysis, rather
than haemodialysis.93 ESRD may be asymptomatic other than
pruritus,98,99,101 and so urea and electrolytes should be
included in a screen for GPWOR. A recent study suggests that C-
reactive protein levels in any one patient positively correlate
with the incidence of uraemic pruritus.102
Dry skin (xerosis) is the most common cutaneous sign in
patients on dialysis, although this does not necessarily corre-
late with pruritus.103,104 Perhaps uraemic xerosis, even if it is
not the principal cause of pruritus, has a permissive effect by
lowering the threshold for itch.105 Use of emollients is essen-
tial.
No single treatment has been shown overwhelmingly to be
effective. Although the evidence is not compelling, it is com-
mon practice to ensure adequate dialysis, normalize calcium–
phosphate balance, control PTH to accepted levels, correct any
anaemia with erythropoietin and use emollients (for xerosis)
before using other treatment strategies.99,106,107
Pruritus is more common in underdialysed patients and
symptoms may be improved by increasing the dialysis
dose.108 The problem is that dialysis adequacy measured by
Kt/V [(dialyser urea clearance 9 time)/urea distribution vol-
ume] is now generally at least as high as, or higher than, in
the intervention group in these trials. There are no data corre-
lating an optimum dialysis adequacy to reduce symptoms such
as pruritus, but current guidelines suggest that a Kt/V of
around 16 is optimal.109 In addition, an RCT has shown that
high-flux haemodialysis is more effective in treating uraemic
pruritus than haemodialysis filtration.110
Secondary and tertiary hyperparathyroidism often accom-
pany ESRD and may contribute to pruritus (see section 7.5).
Topical capsaicin, a natural alkaloid extracted from chilli pep-
pers, depletes neuropeptides including substance P in peripheral
sensory neurons. A randomized, double-blind crossover trial of
19 patients on haemodialysis with severe pruritus showed a sta-
tistically and clinically significant effect of capsaicin 0025%
cream applied four times daily for 4 weeks compared with pla-
cebo cream. Fourteen (out of 17) patients completing the study
reported marked relief, with five of the 14 reporting complete
remission of pruritus. Furthermore, in the responders, there
was a prolonged antipruritic effect up to 8 weeks after cessation
of treatment. There were no serious side-effects, but one patient
died of unrelated myocardial infarction and another had an
insufficient response to treatment.111
A double-blind crossover RCT with 34 patients on
haemodialysis using capsaicin 003% cream four times a day
for 4 weeks on itchy areas also showed a statistically signifi-
cant improvement in pruritus scores (based on severity, distri-
bution and sleep disorder).112 A further open-label study of
22 patients on haemodialysis showed some improvement with
topical capsaicin 0025% cream for 6 weeks; however, 12
patients did not complete the trial, with eight citing unaccept-
able cutaneous ‘burning sensation’. A total of seven (out of
nine) patients completing the trial showed improvement in
symptoms.113 In summary, there is evidence for a positive
effect of capsaicin cream, although trial numbers have been
small.
Topical tacrolimus may be effective at controlling uraemic
pruritus in individual cases.114,115 However, these observa-
tions are not confirmed in RCTs in uraemic pruritus.116,117
Recently, topical calcipotriol has been shown to have antipru-
ritic effects in renal itch, in an open-label, pilot study on 23
patients.118
An RCT comparing topical cromolyn sodium (sodium cro-
moglicate) 4% with placebo showed that the former was
effective at treating uraemic pruritus.119 A double-blind cross-
over RCT of c-linolenic acid in 14 patients on haemodialysis
and three patients on peritoneal dialysis showed significant
improvement of visual analogue rating in the treatment group
(by approximately 50%). Treatment included daily application
to the whole body (after bathing) and thrice-daily application
to pruritic sites with evening primrose oil for 2 weeks. Only
one patient withdrew from the study due to a skin rash.120
Oral antihistamines may be effective in uraemic pruritus, but
there are no RCTs. Ketotifen 1 mg daily, in five patients,
showed marked improvement in symptoms over 8 weeks.121 A
study of 24 patients on haemodialysis used doxepin 10 mg
twice daily followed by washout and crossover with placebo for
1 week each. Complete resolution of symptoms was reported in
58% of the treatment group vs. 8% on placebo, and relative
improvement in 29% vs. 17%, respectively. One-half of patients
(50%) reported drowsiness and one patient withdrew from the
study.122 A recent prospective cohort study suggested that long-
term sedative antihistamines may predispose to dementia and
should be avoided, except in palliative situations, although this
was not in a specific uraemic population.123 Cetirizine 10 mg
daily, a mildly sedating antihistamine, did not help with urae-
mic pruritus in patients on haemodialysis.124
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Oral gabapentin has been shown to be effective in uraemic
pruritus, usually given in a dose of 100–300 mg after dialysis
three times per week. A double-blind, placebo-controlled trial
of 34 patients on haemodialysis with pruritus unresponsive to
oral antihistamines received 400 mg gabapentin twice weekly
after the haemodialysis session for 4 weeks. Note that these are
low doses compared with the non-ESRD population. There was
a significant improvement in the treatment group compared
with placebo, with mild side-effects of drowsiness in the treat-
ment group.125 Gabapentin 300 mg given three times a week
after dialysis sessions, with a crossover and washout period with
placebo, reduced pruritus in 25 adult patients on haemodialy-
sis.126 Gabapentin has been shown in a small study (n = 14) to
improve sleep and depression associated with pruritus in
patients on dialysis.127 The minimal effective dose of gabapentin
is not known, but a multicentre, double-blind, placebo-con-
trolled trial of 34 patients receiving 100 mg postdialysis, three
times a week, showed good response rates, with the visual ana-
logue rating falling in excess of 50% compared with placebo.128
A recent RCT suggested that the beneficial effect of gabapentin
in treating pruritus in patients receiving haemodialysis was not
significantly different from the effect of ketotifen.129
One RCT showed that another GABA analogue, pregabalin,
may also be effective in uraemic pruritus at a dose of 75 mg
twice daily orally.130
Three 5-HT3 receptor antagonists that have been tried in
uraemic pruritus are ondansetron, granisetron and tropisetron.
Initial case reports suggested that both ondansetron 8 mg
daily orally131 and granisetron 1 mg daily orally132 were
effective. However, a larger open study looking at the effects
of ondansetron (8 mg daily orally) and tropisetron (5 mg
daily orally)124 and an RCT looking at ondansetron130 do not
support the use of these agents.
Naltrexone is an opioid antagonist used 50 mg daily orally,
which has been used with mixed results in uraemic pruritus.
An earlier RCT showed that it was effective,133 but a more
recent RCT found that it was ineffective and had a high inci-
dence of adverse effects.114 Naltrexone is not a first-choice
agent in treating uraemic pruritus.134
Thalidomide has been trialled in 11 patients with severe
uraemic pruritus with seven in a control arm. The treatment
group received thalidomide 100 mg at night for 7 days fol-
lowed by washout and crossover to placebo. The mean pruri-
tus score was decreased by more than 50% in six of the 11
patients in the thalidomide group and in none of the placebo
group. One limitation of this study was the fact that pruritus
was scored on a scale of 1 to 3.135
Mirtazapine 15–30 mg daily orally may have a role in
managing cases of uraemic pruritus, through its antianxiety
properties,51 as may sertraline 25–200 mg daily orally, as
shown in a large case series.136
An RCT of oral activated charcoal in uraemic pruritus in
individuals on chronic renal dialysis showed significant
improvements in symptoms.137
The effects of phototherapy on uraemic pruritus are dis-
cussed in section 8.3. The role of acupuncture in treating
uraemic pruritus is discussed in the section on alternative ther-
apies (section 8.4).
In summary, urea and electrolytes should form part of the
investigation of GPWOR. There is some evidence to support
treatment of uraemic pruritus with a variety of topical and
oral agents. Uraemic pruritus is associated with increased mor-
tality, and renal transplantation is the only definitive treatment
for this condition.99
Recommendations (investigation)
• Urea and electrolytes should form part of the investiga-
tion of GPUO (Strength of recommendation D; Level of evi-
dence 3)
Recommendations (treatment)
• Ensure adequate dialysis, normalize calcium–phosphate
balance, control PTH to accepted levels, correct any
anaemia with erythropoietin and use simple emollients
(for xerosis) in patients with uraemic pruritus before
using other treatment strategies (Strength of recommendation
D; Level of evidence 3)
• No single topical or systemic treatment strategy is
effective:
○ Consider capsaicin cream, topical calcipotriol or
oral gabapentin (Strength of recommendation D; Level of
evidence 3)
○ Sedative antihistamines long term may predis-
pose to dementia and should be avoided, except
in palliative care (Strength of recommendation B; Level
of evidence 2++)
○ Cetirizine is not an effective antihistamine in
uraemic pruritus (Strength of recommendation D; Level
of evidence 3)
• Renal transplantation is the only definite treatment
(Strength of recommendation D; Level of evidence 3)
7.7 Hepatic pruritus
Pruritus is a common symptom in patients with various hepa-
tobiliary disorders, including cholestasis of pregnancy.138–140
The skin in hepatic pruritus is often generally hyperpigmented
and excoriated.141 The hands and feet are often the worst-
affected areas.139 Pruritus in association with fatigue at presen-
tation may be a marker for more aggressive disease, for exam-
ple primary biliary cholangitis.142
There is a poor correlation between pruritus and bile acid
levels, suggesting that other factors may be relevant.138,139
In patients with large bile duct obstruction, treatment is
directed at restoration of biliary drainage, which is often
associated with a prompt resolution of symptoms.138,139
Nevertheless, measurement of serum bile acids may be
important in detecting asymptomatic cholestasis in associa-
tion with pruritus.143 Ursodeoxycholic acid is frequently
used to treat cholestasis of a range of causes, including
cholestasis of pregnancy and primary biliary cholangitis.
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For pruritus associated with parenchymal liver disease,
cholestyramine is often given as first-line therapy, although
there is limited evidence. Cholestyramine, colestipol and cole-
sevelam (anion exchange binding resins) bind bile salts in the
gut lumen, thus preventing absorption of bile acids in the ter-
minal ileum.144,145 A meta-analysis of several RCTs involving
cholestyramine use suggested that the data were too heteroge-
neous to pool.144 However, one small, double-blinded RCT
showed a beneficial effect in 10 patients, using cholestyramine
9 g daily orally.145
Rifampicin is often considered the second-line choice. Start-
ing at a dose of 150 mg twice daily, the dose can be
increased to 600 mg twice daily.146 Patients should be moni-
tored for hepatotoxicity and informed about the change of
colour to secretions.146 Two meta-analyses of a small number
of RCTs suggest that rifampicin is effective in reducing hepatic
pruritus.144,147 Given this evidence, rifampicin should now be
the drug of first choice in treating hepatic pruritus.
Naltrexone 50 mg daily orally or sertraline 75–100 mg
daily orally have been considered as third-line choices.138,139
In a meta-analysis comparing the effects of cholestyramine,
rifampicin and opioid antagonists, both opioid antagonists and
rifampicin were shown to reduce pruritus.144 However, rifam-
picin was not found to have increased side-effects when com-
pared with placebo, unlike the opioid antagonists.144 Opioid
antagonists have significantly more side-effects than
cholestyramine and rifampicin, and this may limit their use in
hepatic pruritus.144,148 There is one small RCT that supports
the use of sertraline 75–100 mg in hepatic pruritus. The drug
was well tolerated.149 Sertraline should be the third-line
choice before naltrexone. Nalmefene (025–1 lg kg1 per
day intravenously) may be an alternative opioid antagonist to
naltrexone,150,151 as may methylnaltrexone152 and naloxone.153
Ondansetron was found to be helpful in hepatic pruritus in
two early RCTs,154,155 but not in two more recent
RCTs.156,157 There has been no meta-analysis of its role in
therapy as yet. It is difficult to support the routine use of
ondansetron in the management of hepatic pruritus.
A number of agents have had beneficial effects in individual
cases or case series of hepatic pruritus, including systemic
dronabinol,158 phenobarbitone159 and propofol,160,161 as well
as topical tacrolimus ointment.162
Gabapentin did not improve hepatic pruritus in an RCT. In
fact, it made the itch worse in general.163 Gabapentin cannot
be recommended in hepatic pruritus.
Physical treatments that have been tried in hepatic pruritus
include phototherapy (see section 8.3), extracorporeal dialysis
techniques, nasobiliary drainage and liver transplanta-
tion.138,139,164 These latter three are part of specialist hepato-
logical practice and are not detailed further.
Experimental evidence suggests that new specific agents
based on blockade of bile acid transport, autotaxin and
lysophosphatidic acid metabolism in the liver may improve
hepatic pruritus in the future.165
Hepatitis in GPWOR is discussed in section 7.10: infections,
infestations and generalized pruritus.
Recommendations (investigation)
• Liver function tests should form part of the investigation
of GPWOR. Perhaps consider bile acids and antimito-
chondrial antibodies. Any suggestion of significant hep-
atic impairment should lead to a referral to a hepatology
centre (Strength of recommendation D; Level of evidence 3)
Recommendations (treatment)
• In patients with hepatic pruritus, consider rifampicin as
first-line treatment (Strength of recommendation A; Level of evi-
dence 1+)
• In patients with hepatic pruritus consider cholestyra-
mine as second-line treatment (Strength of recommendation D
(GPP); Level of evidence 4)
• In patients with hepatic pruritus consider sertraline as
third-line treatment (Strength of recommendation D (GPP); Level
of evidence 4)
• Naltrexone or nalmefene are considered fourth-line
treatments (Strength of recommendation D (GPP); Level of evidence
4)
• In patients with hepatic pruritus consider as fifth-line
treatment
○ systemic dronabinol, phenobarbitone, propofol or
topical tacrolimus ointment (Strength of recommendation
D; Level of evidence 3)
○ new specific agents based on blockade of bile acid
transport, autotaxin and lysophosphatidic acid meta-
bolism (Strength of recommendation D; Level of evidence 4)
○ phototherapy, extracorporeal dialysis techniques,
nasobiliary drainage and liver transplantation
(Strength of recommendation D; Level of evidence 3)
• In patients with hepatic pruritus do not use gabapentin
(Strength of recommendation D (GPP); Level of evidence 4)
7.8 Neuropathic pruritus
Neuropathic pruritus is caused by pathology located at any
point along the afferent pathway of the nervous system.166 This
can arise due to pathology affecting the peripheral nervous sys-
tem causing postherpetic neuropathy, brachioradial pruritus or
notalgia paraesthetica, or due to lesions affecting pathways of
the central nervous system, for example as a result of spinal
cord tumours, neurofibromatosis type 1 or multiple sclero-
sis.166,167 Sensory symptoms including burning, paraesthesia,
stinging and tingling can accompany neuropathic pruri-
tus.166,167
Nerve fibre compression can cause pruritus in the corre-
sponding dermatome, and nerve fibre degeneration (such as
small fibre neuropathy) can cause a localized or generalized
pruritus. Small fibre neuropathy can occur in systemic diseases
such as diabetes mellitus, Guillain–Barre syndrome, sarcoidosis,
neurofibromatosis type 1 and HIV.167,168 Diabetic neuropathy
can lead to a regional pruritus affecting the trunk.97 Small fibre
neuropathy may be too small to produce clinical or
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electrophysiological changes, and the only investigation that
may reveal anything is skin biopsy.
As in the majority of cases, the pruritus is not generalized;
neurological causes of pruritus will not be discussed further in
this review.166,168 Following a detailed history, examination
and initial investigations, the patient should be referred to the
relevant specialist, except in the case of clinically obvious notal-
gia paraesthetica or brachioradial pruritus, which can often be
managed in primary care.166,168 Detailed investigation of the
nervous system is not usually part of the investigation of gener-
alized pruritus, unless it is clinically indicated.
Recommendations (investigation)
• Following a detailed history, examination and initial
investigations, a patient with neuropathic pruritus may
need to be referred to the relevant specialist (Strength of
recommendation D (GPP); Level of evidence 4)
• Detailed further investigation of the nervous system is
advised only if it is clinically indicated (Strength of recom-
mendation D (GPP); Level of evidence 4)
Recommendations (treatment)
• Patients with neuropathic pruritus should be referred
to the relevant specialist for treatment (Strength of recom-
mendation D (GPP); Level of evidence 4)
7.9 Psychological and emotional factors in pruritus
Pruritus can be triggered or worsened by negative feelings
such as stress or emotional excitation including rage, fear,
annoyance and embarrassment, as well as other cognitive fac-
tors.169–171 Viewing itch-related images and simple verbal
suggestion have also been shown to elicit pruritus, clearly
demonstrating the importance of psychological factors.172,173
There appears to be a direct correlation between the inci-
dence of stressful major life events and cutaneous sensory
symptoms, including pruritus.174 Minor daily stressors may
also contribute to pruritus.175 Stress may cause pruritus via
activation of neural circuits in the hippocampus and subcorti-
cal structures.176 Scratching appears to have a similar effect to
sedative antihistamines, in terms of effects on neural activity,
in relieving stress-induced pruritus.176
Chronic generalized pruritus of any cause significantly
reduces quality of life in a manner akin to chronic pain.7,177
Deranged sleep patterns are common and contribute to exacer-
bations of itching and further difficulty coping.7 Significant
psychosocial morbidity, including anxiety and depressive dis-
order, develops in up to one-third of individuals with chronic
pruritus.7,178–180 Feelings of stigmatization are common, and
perceived body image may become distorted.181
Chronic generalized pruritus is found commonly in several
psychiatric disorders including depression, anxiety disorder,
obsessive compulsive disorder, substance abuse and delu-
sional infestation.7,182–185 However, one should always look
for a physical cause before labelling such patients as ‘psy-
chogenic’. The French psychodermatology group proposed
that psychogenic pruritus should be renamed ‘functional itch
disorder’. Relevant diagnostic criteria are outlined in
Table 4.182
A nursing programme ‘Coping with Itch’ included educa-
tion on how to avoid trigger factors, how to apply treatments,
lifestyle interventions, patient support groups, relaxation tech-
niques and changes to cognition and behaviour.186 A con-
trolled study found no significant difference in the intensity of
itch; however, a significant improvement in itch-related cop-
ing was found in the intervention group.187,188 The frequency
of visits was reduced, with 59% of the intervention group vis-
iting the dermatologist in the first 3 months compared with
86% of the controlled group. The programme led to a reduc-
tion in the frequency of itch and scratching, a reduction in
catastrophizing thoughts and improvements in coping with
helplessness in patients in the period immediately following
the intervention.
A holistic biopsychosocial assessment of any distressed
patient with chronic pruritus is recommended. This includes
screening for depression and anxiety, quality-of-life impact,
ongoing stressors and recent major life events, and beliefs
related to pruritus. Neuroactive medications are often used in
psychogenic pruritus (functional itch disorder), including
gabapentin, antidepressants, low-dose neuroleptics and mir-
tazapine.7 However, medications that may benefit psychogenic
pruritus can also cause drug-induced pruritus (see section
7.11), for example topiramate.189,190
Input from clinical psychology and/or psychiatry should
always be considered. The potential role of new psycho-
logical approaches that have proved effective in chronic
pain is also promising in the management of chronic pru-
ritus and merits further research including acceptance and
commitment therapy and mindfulness-based stress reduc-
tion.191
Table 4 Proposed diagnostic criteria for psychogenic pruritus
(functional itch disorder)
Three compulsory criteria
Three out of seven optional criteria
are also required
Generalized pruritus
without primary skin
disease
Chronological relationship of the
occurrence of pruritus with one or
several life events that could have
psychological repercussions
Chronic pruritus
(> 6 weeks)
Variations in intensity associated
with stress
No somatic cause
(cutaneous or systemic)
Pruritus that is worse at night
Predominance during rest or
inaction
Associated psychological disorder
Pruritus that could be improved by
psychotropic drugs
Pruritus that could be improved by
psychological therapy
© 2017 British Association of Dermatologists British Journal of Dermatology (2018) 178, pp34–60
BAD guidelines for generalized pruritus, 2018, G.W.M. Millington et al. 43
Recommendations (treatment)
• In distressed patients with chronic pruritus including
likely psychogenic origin, consider psychosocial and
behavioural interventions including education on how
to avoid trigger factors, how to apply treatments, life-
style interventions, relaxation techniques, cognitive
restructuring and behaviour modification including
habit reversal training (Strength of recommendation D (GPP);
Level of evidence 4)
• Patient support groups can be beneficial (Strength of rec-
ommendation D (GPP); Level of evidence 4)
• Referral to social workers, liaison psychiatry and psy-
chologists may be helpful in individual cases (Strength of
recommendation D (GPP); Level of evidence 4)
7.10 Infections, infestations and generalized pruritus
Pruritus due to cholestasis is associated with many viral infec-
tions, including hepatitis A, B, C and E.138,192 Pruritus typi-
cally occurs at a late stage of infection with HIV, although
occasionally it may be a presenting feature.193 The degree of
pruritus in HIV infection often correlates directly with the
viral load and can be associated with eosinophilia.194 Causes
of pruritus in HIV include xerosis, drug therapies and photo-
sensitivity, together with specific follicular and papular der-
matoses, such as eosinophilic folliculitis.193 Scabies should
always be considered, which can present with severe pruritus
and minimal skin signs, particularly in patients with HIV.195
Phototherapy in HIV-induced pruritus is discussed later (see
section 8.3). In one case–control study, indomethacin
(25 mg, three times per day) proved more effective at reduc-
ing HIV pruritus than sedating antihistamines, although gastric
intolerance was observed in several patients.196 In one case
series, hypnosis significantly reduced HIV-related itch.197 Vari-
cella zoster infection, which is also commonly associated with
HIV infection, may be associated with postherpetic pruritus,
rather than neuralgia.198
Eosinophilia and generalized pruritus are features of para-
sitic infections, notably helminths such as Strongyloides sterco-
ralis.199 Treatment of onchocerciasis with any microfilaricide
may cause prolonged itching, with or without oedema and
exfoliation.200 Swimmers bathing in lakes and rivers world-
wide are at risk of intense pruritus within minutes, due to
skin penetration by cercariae of schistosomes (Trichobilharzia
spp. in Western Europe).201 In some schistosome infections
this is followed by a toxaemic phase (e.g. Katayama fever
due to Schistosoma japonicum).202 Chikungunya fever may also
present with generalized pruritus.203
Chloroquine therapy of malaria is considered in section
7.11.
Recommendations (investigation)
• Take a full history (including travel history, sexual his-
tory and history of potential intravenous drug abuse)
and examination; consider:
○ HIV, hepatitis A, B and C serology
○ Screening for malaria, strongyloidiasis and schisto-
somiasis (Strength of recommendation D (GPP); Level of evi-
dence 4)
Recommendations (treatment)
• In patients with generalized pruritus associated with
HIV consider indomethacin 25 mg three times per
day, orally (Strength of recommendation D; Level of evidence 3)
• In patients with generalized pruritus associated with
HIV consider hypnosis to relieve itch (Strength of recom-
mendation D; Level of evidence 3)
7.11 Drug-induced pruritus
Pruritus secondary to the effects of medication may occur
with or without a rash. It is important to obtain a history
of all ingested medication, including over-the-counter phar-
maceuticals and herbal remedies. In a study of 200 patients
with cutaneous drug reactions, 125% had pruritus without
a rash.204 Proposed mechanisms of drug-induced pruritus
include cholestasis, direct drug or metabolite deposition and
alteration of neural signalling.205 However, the majority of
cases are idiopathic.205 Recently, generalized pruritus has
been associated with chronic heart failure, but this is cur-
rently thought to be related to the treatment of the under-
lying cardiac condition, rather than any effect of chronic
heart failure on the skin.206 Cholestatic pruritus and its
management are discussed elsewhere in these guidelines
(see section 8.3). This section will focus on the manage-
ment of opioid- and chloroquine-induced generalized pruri-
tus without visible skin signs.
Opioid-induced pruritus is common and affects 2–10% of
patients receiving oral, 10–50% intravenous and 20–100%
epidural and intrathecal opioids.207 The frequency increases
with increased dosage of opioids.207 Treatments include opioid
antagonists (naloxone, naltrexone, nalmefene, methylnaltrex-
one), opioid agonist antagonists (nalbuphine, butorphanol),
droperidol, ondansetron, propofol, diclofenac and antihis-
tamines.207 The use of opioid antagonists in treating opioid-
induced pruritus clearly risks inducing significant pain.
Naltrexone is a commonly used l-opioid receptor antago-
nist useful for treatment of opioid and alcohol dependence.208
It was tested in two studies at 3-mg, 6-mg and 9-mg doses in
women receiving epidural morphine as postcaesarean section
analgesia. Both 6 mg and 9 mg were effective in reducing
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pruritus, but with reduction of duration of analgesia com-
pared with control.209
Methylnaltrexone is a derivative of naltrexone with less lipid
solubility than naltrexone, which reduces its ability to cross
the blood–brain barrier.207 In a double-blind, placebo-con-
trolled study, it reduced the subjective feeling of ‘skin itch’ at
an oral dose of 192 mg kg1, 3 min after injection of
005 mg kg1 of intravenous morphine.210
Nalbuphine and butorphanol are synthetic j-opioid receptor
agonists that are available only as injections. There are data to
suggest antipruritic efficacy of nalbuphine209 and butor-
phanol,211 but these are unlikely to be useful outside the critical
care setting.
Ondansetron and other 5-HT3 receptor antagonists (tropise-
tron and granisetron) do not reduce the incidence of opiate-
induced pruritus or time to onset of pruritus when compared
with placebo.212 However, ondansetron 4 mg or 8 mg may
reduce the severity or the need for treatment of pruritus sec-
ondary to opiates,212 although this has been refuted in a more
recent study.213
Droperidol is a parenteral antidopaminergic drug. It may
prevent opiate-induced pruritus when given intravenously
(25–5 mg).209
Diclofenac 100 mg, given rectally to 105 patients postin-
duction for abdominal surgery in an unblinded RCT, reduced
postoperative pruritus.214
Mirtazapine 30 mg daily orally215 and gabapentin 1200 mg
daily in divided doses orally216 in RCTs have both been shown
to prevent morphine-induced pruritus in a surgical setting.
Chloroquine-induced pruritus during malaria treatment
occurs in 60–70% of patients of African background.217,218 It is
often severe and generalized without skin lesions. It is uncom-
mon in other ethnic groups and the molecular basis for this
potential pharmacogenetic effect is unclear.217–219 There may
be interindividual variation in chloroquine metabolism.220
Other potential aetiological factors in chloroquine-induced pru-
ritus include the age of the affected individual, degree of plas-
modium parasitaemia, species of plasmodium, dosage form of
chloroquine and excipients of the preparation.221
A double-blind RCT compared promethazine (25 mg daily
orally), prednisolone (10 mg daily orally), niacin (50 mg daily
orally) and a combination of prednisolone with niacin.217 Pruri-
tus was reduced by prednisolone alone, niacin alone and a com-
bination of prednisolone and niacin. The prednisolone-only and
combination groups showed the greatest efficacy when the sever-
ity was adjusted to plasmodium parasite density.217
Naltrexone (50 mg daily orally) showed no effect on
chloroquine-induced pruritus intensity, when compared with
promethazine in a small, double-blind RCT involving 18
patients of whom six dropped out.218
Dapsone (50 mg daily orally) reduced chloroquine-induced
pruritus and limb-scratching activity significantly, whereas
ketotifen, clemastine and prednisolone had no effect in a par-
allel-group trial.222
Apart from the opioids and chloroquine, some drugs com-
monly reported to cause pruritus include angiotensin-
converting enzyme inhibitors and statins, although the list of
potential drugs is extensive.205 Interestingly, epidural dexam-
ethasone has been associated with causing generalized pruri-
tus.223
A trial of cessation of medications should be undertaken if the
risk vs. benefit analysis is acceptable to the clinician and patient.
Recommendations (investigations)
• In patients with drug-induced pruritus, a trial of cessa-
tion of medications should be undertaken if the risk vs.
benefit analysis is acceptable to both clinician and patient
(Strength of recommendation D (GPP); Level of evidence 4)
Recommendations (treatment)
• Naltrexone is effective in treating opioid-induced general-
ized pruritus without visible skin signs and is the first-
choice recommendation in this situation (if cessation of
opioid therapy is impossible). Methylnaltrexone may be
an alternative (Strength of recommendation B; Level of evidence 1+)
• In patients with opioid-induced generalized pruritus
without visible skin signs consider methylnaltrexone,
ondansetron, droperidol, mirtazapine or gabapentin as
alternative antipruritic agents (Strength of recommendation D
(GPP); Level of evidence 4)
• In patients with postoperative generalized pruritus with-
out visible skin signs consider diclofenac given rectally
(Strength of recommendation D (GPP); Level of evidence 4)
• In patients with chloroquine-induced generalized pruritus
without visible skin signs consider prednisolone 10 mg,
niacin 50 mg or a combination of prednisolone and niacin
(Strength of recommendation D (GPP); Level of evidence 4)
• In patients with chloroquine-induced generalized pruri-
tus without visible skin signs consider dapsone to relieve
itch (Strength of recommendation D (GPP); Level of evidence 4)
8.0 Treatment of generalized pruritus of
unknown origin
Once both underlying pruritic skin disease and other sec-
ondary causes of pruritus have been excluded, an individual
can be considered to have idiopathic GPUO. This must also be
distinguished from pruritus of elderly skin (see section 9.2). It
is important to keep an open mind to the possibility of symp-
toms and signs of secondary pruritus developing later in an
apparent case of GPUO, therefore necessitating reinvestigation.
8.1 Topical treatments for generalized pruritus of
unknown origin
For treatment of secondary pruritus, see sections 8.3 and 8.4.
Although most dermatologists would recommend that
patients with pruritus should use emollients to wash and
moisturize the skin, and avoid the use of soaps and physical
triggers to pruritus such as wearing clothing made of wool,
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there is little direct evidence to support these practices in
the literature. The evidence is mostly indirect extrapolation
from studies involving the management of xerosis and
eczema.224 Many patients will self-medicate with proprietary
emollients and most dermatologists will prescribe these as
the first step in managing GPUO, despite the lack of objec-
tive evidence.
A recent meta-analysis of 19 RCTs and other trials of topical
antihistamines suggested that topical doxepin has a role in the
management of generalized pruritus, but the evidence for other
compounds was lacking.225 However, concerns about the risk of
allergic contact dermatitis to topical doxepin suggest that treat-
ment should be limited to 8 days, and toxicity concerns limit
use to 10% of body surface area (maximum 12 g daily).226
Crotamiton 10% lotion227 was considered not to have a sig-
nificant antipruritic effect compared with vehicle in an RCT.
Menthol was thought to have a counter-irritant effect (which
may be beneficial), rather than a true antipruritic effect com-
pared with vehicle control.228 Calamine lotion is not recom-
mended in the treatment of pruritus, as there is no literature
to support its use in GPUO.
Topical capsaicin has been promoted as an antipruritic agent
in a variety of small studies. However, a systemic review of
the literature does not support its use in this context,229
except in uraemic pruritus (see section 7.6). We do not rec-
ommend its use in treating GPUO.
Other agents that have been promoted as having a topical
antipruritic effect in double-blind RCTs include the topical
anaesthetic spray ethyl chloride in placebo-controlled stud-
ies,230,231 the topical tricyclic antidepressants amitriptyline and
diphenhydramine, compared with vehicle control232 and the
moderate-potency topical steroid clobetasone butyrate.233 Only
clobetasone butyrate and hydrocortisone are available for
over-the-counter use in the U.K.
Recommendations
• Patients with GPUO may be prescribed topical dox-
epin. Treatment should be limited to 8 days, 10% of
body surface area and 12 g daily (Strength of recommenda-
tion D (GPP); Level of evidence 4)
• Patients with GPUO may benefit from topical clobeta-
sone butyrate or menthol (Strength of recommendation D;
Level of evidence 4)
• Patients with GPUO should not use crotamiton cream
(Strength of recommendation B; Level of evidence 1+)
• Patients with GPUO should not use topical capsaicin or
calamine lotion (Strength of recommendation D (GPP); Level of
evidence 4)
8.2 Systemic treatments for generalized pruritus of
unknown origin
Various systemic treatments have been used in the manage-
ment of idiopathic GPUO. However, no RCTs have found any
one therapy to be effective and safe. Most publications are case
reports, case series or open trials with no long-term follow-
up. It is important to exclude secondary causes of pruritus that
have specific treatments.
Blockade of the histamine H1 receptor subtype, either
peripherally or in the central nervous system, may help
reduce the sensation of itch.234 Chlorpheniramine 4 mg
and cimetidine 400 mg (H1 and H2 antagonists) in combi-
nation, taken four times per day, showed suppression of
pruritus artificially induced by intraepidermal histamine and
the artificial pruritogen papain, suggesting the need for
simultaneous antagonism of more than one histamine
receptor to control itch.235 Other sedative antihistamines,
such as hydroxyzine 25 mg daily orally, improved his-
tamine-induced pruritus.236 Nonsedative drugs such as fex-
ofenadine 180 mg or loratadine 10 mg, or mildly sedative
agents such as cetirizine 10 mg are now preferred to seda-
tive drugs such as chlorpheniramine and hydroxyzine,
because of the risk of potentiating dementia.123,237
Nonsedative antihistamines may be used once daily, or up
to four times a day as required.237 An open-label study
suggested that oral cetirizine (dose not specified) was
preferable, more cost-effective and less time consuming
than narrowband (NB)-UVB phototherapy in the manage-
ment of generalized pruritus.238
Tricyclic and SSRI antidepressants are often prescribed by
clinicians in the management of GPUO, in the absence of psy-
chological disease. In a large case series in GPUO, and in non-
dermatological secondary pruritus, both paroxetine 10 mg
daily and fluvoxamine 25 mg daily improved pruritus in
GPUO.238,239 Mirtazapine 15 mg daily orally had similar
effects in a smaller case series.240
Naltrexone 50 mg daily orally, an oral opioid antagonist,
has been shown to reduce histamine-induced pruritus.241
Butorphanol (1 mg daily or every other day), a j-opioid ago-
nist and l-opioid antagonist, also suppressed itch in cases of
GPUO.242
Two GABA analogues, gabapentin243,244 and prega-
balin,245 reduced itch in cases of GPUO. Gabapentin should
be started at 300 mg on the first day, then 300 mg twice a
day and then increased to 300 mg three times a day on
the third day.243,244 Gabapentin can then be increased up
to 600 mg three times a day over 3–4 weeks if there is no
effect.243 In one study pregabalin was started at a dose of
75 mg twice daily and increased to 150 mg twice daily
after 5–8 weeks.245
Ondansetron 8 mg, administered intravenously, may be of
benefit in isolated cases of GPUO.246
Azathioprine, in a dosage range between 25 mg and
175 mg daily, appeared to reduce pruritus in a large case ser-
ies of GPUO, although a high proportion of patients had side-
effects, with some serious enough to stop therapy.247 Aprepi-
tant 80 mg daily orally, an antagonist of neurokinin receptor
1 that mediates the actions of substance P on somatosensory
neurones, reduced pruritus in a few cases of GPUO, as well as
other cases of secondary pruritus.248
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Recommendations
• In patients with generalized pruritus no one therapy
has been found to be effective and safe. Consider the
following to relieve itch:
○ nonsedative antihistamines such as fexofenadine
180 mg, loratadine 10 mg or mildly sedative
agents such as cetirizine 10 mg before sedative
antihistamines (Strength of recommendation D; Level of evi-
dence 2+)
○ paroxetine, fluvoxamine, mirtazapine, naltrexone,
butorphanol, gabapentin, pregabalin, ondansetron
or aprepitant (Strength of recommendation D; Level of evi-
dence 3)
○ H1 and H2 antagonists in combination, for exam-
ple fexofenadine and cimetidine (Strength of recom-
mendation D (GPP); Level of evidence 4)
○ sedative antihistamines in the short-term or pallia-
tive setting, for example hydroxyzine (Strength of rec-
ommendation D; Level of evidence 3)
8.3 Phototherapy in generalized pruritus without rash
There is now some evidence for phototherapy in the manage-
ment of secondary pruritus due to underlying systemic disease,
rather than GPUO, although expert opinion suggests benefit in
GPUO. The best-quality evidence for use of phototherapy for
pruritus is in treating uraemic pruritus.249 A meta-analysis of
RCTs in treating moderate-to-severe uraemic pruritus concluded
that broadband (BB)-UVB phototherapy was the treatment of
choice, as it was the only therapy to reach clinical signifi-
cance.249 In a half-body BB-UVB trial in which UVA was used as
an active comparator, all patients with uraemic pruritus
improved with BB-UVB only on the half-side treated, and the
authors suggested that BB-UVB had systemic actions in relieving
pruritus.250 Onset of effect was noticed from 2 weeks into treat-
ment and lasted up to 7 months.250 Two prospective studies of
NB-UVB showed that 60–80% of patients were responders with
a decrease in visual analogue scale scores of 542% and 708%,
respectively.251,252 However, some have not been able to repli-
cate the beneficial response with NB-UVB.253,254
The first single-blind RCT looking at NB-UVB rather than
BB-UVB found no difference between NB-UVB and placebo in
reducing itch in uraemic pruritus.254 Further NB-UVB RCTs
are needed to ascertain any benefit and confirm the optimal
dose and frequency in the management of uraemic pruritus.
There are case series and case reports demonstrating that
both NB-UVB and BB-UVB are effective in providing some
relief of the pruritus associated with PV.59,255–258 Response
rates varied from 50% to 80%.59 Relapses often occurred after
stopping treatment, but maintenance was reported up to
8 months.59 PUVA gave benefit after UVB failed to achieve
complete remission, but again relapses were reported from as
early as 2 weeks after stopping.259 PUVA with natural sunlight
may also be beneficial.260
Temporary relief of pruritus associated with Hodgkin dis-
ease and NHL was reported when treated with BB-UVB and
NB-UVB, respectively.42,52
The use of both PUVA and UVB in case reports and series
has been reported for aquagenic pruritus not associated with
an underlying disorder. Remission was short lived in all
patients, with symptoms recurring 3–24 weeks later.261–263
NB-UVB and BB-UVB gave symptomatic relief in some cases
of aquagenic pruritus,256,264 but in others it was not reported
to be of any benefit.265 After relief obtained with NB-UVB,
once-weekly continued maintenance treatment prevented
relapse of the pruritus.264 Remission for over 1 year was
achieved using combined UVA and UVB.266
BB-UVB may be effective in the management of cholestatic
pruritus, according to several case series.267–269 One single
case used UV (presumably BB-UVB, as it is not stated in the
paper) to induce remission of pruritus that was maintained
with oral cholestyramine.270 Combined UVA and UVB was
used to induce remission of pruritus in a single case of chole-
static pruritus, whereas UVB alone was of no benefit.271
Phototherapy with UVB was found to be an effective treatment
for HIV-associated pruritus, with no adverse effects on viral load
in standard doses, in a prospective cohort of 17 patients, with a
larger nontreated control group.272 Oral PUVA therapy has also
been effective in treating HIV-associated pruritus, in a small case
series.273 Psychogenic excoriation has responded to NB-UVB in a
case series of seven patients.274
Recommendations
• BB-UVB is an effective treatment for many patients
with uraemic pruritus (Strength of recommendation A; Level of
evidence 1+)
• Patients with pruritus associated with Hodgkin disease
may benefit from BB-UVB for temporary relief from
itch (Strength of recommendation D; Level of evidence 3)
• Patients with pruritus associated with NHL may benefit
from NB-UVB for temporary relief from itch (Strength of
recommendation D; Level of evidence 3)
• Patients with pruritus associated with PV may benefit
from NB-UVB, BB-UVB, PUVA or PUVA in combina-
tion with sunlight to relieve itch, although relapse is
common after stopping treatment (Strength of recommenda-
tion D; Level of evidence 3)
• Patients with aquagenic pruritus may benefit from NB-
UVB, BB-UVB or combined UVA and UVB to relieve
itch (Strength of recommendation D; Level of evidence 3)
• Patients with cholestatic pruritus may benefit from BB-
UVB or combined UVA and UVB to relieve itch
(Strength of recommendation D; Level of evidence 3)
• Patients with HIV-associated pruritus may benefit from
UVB phototherapy (Strength of recommendation D; Level of evi-
dence 2+)
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• Patients with HIV-associated pruritus may benefit from
oral PUVA (Strength of recommendation D; Level of evidence 3)
• Patients with psychogenic pruritus (functional itch dis-
order) may benefit from NB-UVB (Strength of recommenda-
tion D; Level of evidence 2+)
• Patients with GPUO often benefit from phototherapy
(Strength of recommendation D (GPP); Level of evidence 4)
8.4 Alternative therapies in generalized pruritus of
unknown origin and secondary pruritus
Traditional Chinese medicine combines acupuncture, a tech-
nique using needles to exert effects through pressure points in
the body, with established herbal remedies. Traditionally,
acupuncture is only part of a range of treatments available in
Chinese medicine and is usually used in combination with
these other therapeutic approaches.24 This approach has been
shown to be successful in generalized pruritus in a single
case.275
Acupuncture may be carried out independently of Chinese
herbal medicine.276 An RCT showed that acupuncture can
prevent histamine-induced itch.277 There is also some evi-
dence for the use of acupuncture in the management of
uraemic pruritus. An RCT showed that acupuncture may be
beneficial,278 but a systematic review suggests that acupunc-
ture does not have a role in the management of uraemic
pruritus.279 Acupuncture was shown, in a partially con-
trolled study, to reduce the pruritus induced by morphine
used for patient-controlled analgesia.280 Currently there is
no robust evidence to recommend acupuncture as a first-
line therapy of pruritus, but as it is relatively safe and has
few side-effects it may always be considered in an individ-
ual situation.24
Acupressure combines massage and pressure to specific
points, along a defined meridian, similar to those used for
acupuncture. Auricular acupressure may be beneficial in urae-
mic pruritus as reported in an unblinded, placebo-controlled
trial.281
Two uncontrolled studies suggest the benefits of aromather-
apy in uraemic pruritus.282,283
Treatments in other uncontrolled studies that may show
benefit in uraemic pruritus include Sericin cream, derived
from silkworms,284 topical turmeric285 and oral omega-3 fatty
acid supplements.286
Transcutaneous electrical nerve stimulation may be of bene-
fit in some patients, as shown by the results of an uncon-
trolled study in hepatic pruritus.287
Recommendations
• Patients with GPUO may consider acupuncture in com-
bination with Chinese herbal remedies as referenced
(Strength of recommendation D; Level of evidence 3)
• Patients with GPUO may consider acupuncture as a
second-line therapy (Strength of recommendation D; Level of
evidence 3)
• Patients with uraemic pruritus may consider auricular
acupressure, topical Sericin, topical turmeric, oral
omega-3 supplements or aromatherapy (Strength of recom-
mendation D (GPP); Level of evidence 3)
• Patients with hepatic pruritus may benefit from tran-
scutaneous electrical nerve stimulation (Strength of recom-
mendation D; Level of evidence 3)
9.0 Management in primary care
9.1 Community perspective
General practice is usually the first point of contact for patients
with pruritus in the U.K. and in other countries with primary
care-based healthcare systems, and therefore all primary care
providers should have an understanding of this condition.
Generalized pruritus may have a significant underlying cause
in 20–30% of cases, and so the general practitioner (GP) or
family physician’s input in diagnosis and management is
invaluable, given the GP’s broad view of the individual’s over-
all health status.30,288 For example, GPs may have invaluable
insight into patients’ drug histories, family history, risk factors
for underlying disease and psychosocial issues.30,288 The nat-
ure of general practice also ensures continuity of long-term
care and, as the underlying systematic cause of pruritus may
not be evident initially, it is important for GPs to follow up
these patients.288
If the initial patient assessment suggests generalized idio-
pathic pruritus, then simple self-care advice (such as keeping
the individual’s nails short) and emollients should be used,
followed by a short trial of a nonsedating antihistamine,123 if
warranted.
There is little evidence on when to refer a patient with gen-
eralized idiopathic pruritus to secondary care, but it is recom-
mended to refer patients where there is diagnostic doubt, or
in those who are distressed by their symptoms, despite pri-
mary care management.289,290
9.2 Pruritus in the elderly
Pruritus in the elderly (Willan’s itch) is very common and
is defined as chronic itching occurring in those aged over
65 years. It is commonly associated with dry skin or xero-
sis, but there may be other factors, including GPUO, malig-
nancy, ageing in nerve fibre bundles and drug-induced
pruritus.291–293 Pruritus alone can very rarely be the pre-
senting feature of bullous pemphigoid, particularly in the
elderly, and so it may be necessary to request relevant
investigations, such as a skin biopsy and indirect
immunofluorescence.294 Loss of free fatty acids in the
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stratum corneum leads to superficial cracks and fissures in
the epidermis,292 which can cause pruritus by producing
asteatotic eczema. This should be managed by emollients
and topical steroids, ideally for at least 2 weeks, prior to
reassessment for alternative underlying causes of pruritus.295
Moisturizers with high lipid content may be preferred in
the elderly.296 The use of sedating antihistamines should be
avoided in the elderly, because of the potential causal asso-
ciation with dementia.123 Gabapentin (300 mg daily) has
been shown to be of benefit in pruritus of elderly skin in
a small case series of seven patients.244
Recommendations (community)
• GPs should regularly follow up patients with generalized
pruritus where the underlying systematic cause is not
evident (Strength of recommendation D (GPP); Level of evidence 4)
• Patients with GPUO should receive
○ self-care advice and emollients (Strength of recom-
mendation D (GPP); Level of evidence 4)
○ followed by a short course of nonsedating anti-
histamine (Strength of recommendation B; Level of evidence
2++)
• Patients with GPUO should be referred to secondary
care if there is diagnostic doubt, or if primary care
management does not relieve symptoms (Strength of rec-
ommendation D (GPP); Level of evidence 4)
Recommendations (elderly)
• Patients with pruritus in elderly skin should initially
receive emollients and topical steroids for a least
2 weeks to treat any asteatotic eczema (Strength of recom-
mendation D; Level of evidence 4)
• Patients with pruritus in elderly skin who have not
responded to the initial treatment should be reassessed
(Strength of recommendation D; Level of evidence 4)
• Moisturizers with high lipid content may be preferred in
the elderly (Strength of recommendation D; Level of evidence 4)
• Patients with pruritus in elderly skin may benefit from
gabapentin (Strength of recommendation D; Level of evidence 3)
• Patients with pruritus in elderly skin should not receive
sedating antihistamines (Strength of recommendation C; Level
of evidence 2++)
• Patients with GPUO should be referred to secondary
care if there is diagnostic doubt, or if primary care
management does not relieve symptoms (Strength of rec-
ommendation D (GPP); Level of evidence 4))
10.0 Economic considerations
There have not been many studies evaluating the economic
impact of secondary pruritus and GPUO. However, there have
been a number of studies from a group looking at psychoso-
cial nursing interventions in the management of pruritus (see
section 7.9). One particular RCT looked at the health
economic implications and found that most expenses were
associated and incurred in the first 3 months of the pro-
gramme.297 The benefits, with regard to days with little itch,
increased beyond 3 months, thus leading to a favourable
incremental and cost-effectiveness ratio.
11.0 Future directions
Future directions in investigation and management of secondary
pruritus and GPUO should reflect the human and psychological
elements of what is a distressing, chronic condition for the
patient. Recent advances in both the neuroscience and
immunopharmacology of pruritus should lead to new therapies.
Molecular studies, perhaps using DNA subtraction analyses, could
be used to look for the core abnormalities common to all the forms
of secondary pruritus. These key pathological steps could be the best
targets for future therapies. However, without recognition of the
clinical psychopathological dimension and cross-cultural agreement
about clinical assessment of pruritus severity, it will continue to be
difficult to implement new therapies.
An important research and clinical objective is to agree on
standardized approaches to assessing severity of pruritus and
its effect on activities of daily living. Another important ques-
tion is whether ‘up-dosing’ of nonsedative antihistamines, in
a similar fashion to their use in urticaria, is of benefit. There
Table 5 Summary of screening in generalized pruritus without rash
Recommended screening in
generalized pruritus
(Strength of recommendation D)
Detailed history
Detailed examination
Ferritin
Full blood count
Urea and electrolytes
Liver function tests
Erythrocyte sedimentation rate (or
C-reactive protein if unavailable)
Chest X-ray
Optional screening tests,
where there is additional
clinical suspicion
(Strength of recommendation D)
Investigation of potential blood loss
Serum bile acids
C-reactive protein
Lactate dehydrogenase
Thyroid function tests
Fasting glucose and glycated
haemoglobin
Calcium and phosphate (and
parathyroid hormone)
Vitamin D
Immunoglobulins
HIV and hepatitis A, B and C
serology
Computed tomography scan of the
neck, thorax, abdomen and pelvis
Magnetic resonance imaging of the
brain and spinal cord
Nerve conduction studies
Malaria, strongyloidiasis and
schistosomiasis screening
Skin biopsy
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are some types of medication that do not appear to have been
tried in pruritus, such as the leukotriene inhibitors – mon-
telukast and zafirlukast – or the new H4 histamine antagonists.
Additionally, further RCTs of NB-UVB are needed to ascertain
its effectiveness in the management of uraemic pruritus.
Table 6 Summary of investigations
Generalized pruritus (iron deficiency) Full blood count and ferritin levels should be checked in all patients with chronic
GPWOR (Strength of recommendation C)
Generalized pruritus (iron overload) LFTs should be considered for patients with generalized pruritus associated with iron
overload (Strength of recommendation D)
Generalized pruritus (blood disorders) Patients with generalized pruritus with suspicion of haematological involvement
should have initial investigations including full blood count, blood film, lactate
dehydrogenase and erythrocyte sedimentation rate (Strength of recommendation D)
Patients with generalized pruritus associated with either PV or suspected lymphoma
should be referred to haematology (Strength of recommendation D)
Patients with persistent, unexplained generalized pruritus should perhaps have a skin
biopsy carried out to ascertain potential cutaneous lymphoma (Strength of
recommendation D)
Patients with generalized pruritus with suspicion of PV (raised haemoglobin or
haematocrit) should have blood samples sent for JAK2 V617F mutation analysis
and/or be referred to haematology (Strength of recommendation D)
In the absence of JAK2 mutation, secondary causes of PV should be investigated by
means of clinical assessment, renal and liver function tests, serum erythropoietin
level, measurement of oxygen saturation, chest X-ray and abdominal ultrasound
(Strength of recommendation D)
Generalized pruritus (malignancy) A thorough history and physical examination should be performed. Full investigation
to rule out malignancy is not routinely recommended (Strength of recommendation C)
Pruritus with appropriate systemic symptoms of malignancy needs tailored
investigations to rule out specific cancers (Strength of recommendation D (GPP))
Oncology patients receiving biological therapies should be asked about pruritus on
review (Strength of recommendation A)
Generalized pruritus (endocrinopathy) Patients with generalized pruritus should not undergo routine endocrine
investigations (including thyroid function tests), unless they present with additional
clinical features suggesting diabetes, other endocrinopathy or renal disease (Strength
of recommendation D)
Vitamin D supplementation may help some affected by GPWOR (Strength of
recommendation D)
Generalized pruritus (uraemia) Urea and electrolytes should form part of the investigation of GPUO (Strength of
recommendation D)
Generalized pruritus (liver disease) LFTs should form part of the investigation of GPUO. Perhaps consider bile acids and
antimitochondrial antibodies. Any suggestion of significant hepatic impairment
should lead to a referral to a hepatology centre (Strength of recommendation D)
Generalized pruritus (neuropathy) Following a detailed history, examination and initial investigations, a patient with
neuropathic pruritus may need to be referred to the relevant specialist (Strength of
recommendation D (GPP))
Detailed further investigation of the nervous system is advised only if it is clinically
indicated (Strength of recommendation D (GPP))
Patients with suspected neuropathic pruritus should perhaps have a skin biopsy
carried out to try to confirm the diagnosis, if small fibre neuropathy is suspected
(Strength of recommendation D (GPP))
Generalized pruritus (infections and infestations) Take a full history (including travel history) and examination. Consider HIV and
hepatitis A, B and C serology. Consider screening for malaria, strongyloidiasis and
schistosomiasis (Strength of recommendation D (GPP))
Generalized pruritus (drug induced) A trial of cessation of medications should be undertaken, if the risk vs. benefit
analysis is acceptable to both clinician and patient (Strength of recommendation D (GPP))
GPUO, generalized pruritus of unknown origin; GPWOR, generalized pruritus without rash; JAK, Janus kinase; LFT, liver function test; PV,
polycythaemia vera.
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Table 7 Summary of treatments
Generalized pruritus (iron
deficiency)
Iron replacement (Strength of recommendation C)
Generalized pruritus (iron
overload)
Venesection or desferrioxamine infusion (Strength of recommendation D)
Generalized pruritus
(lymphoma)
Patients with generalized pruritus associated with lymphoma may have their itch resolved by treatment with
cimetidine, carbamazepine, gabapentin or mirtazapine (Strength of recommendation D)
Patients with generalized pruritus associated with incurable lymphoma may have their itch relieved with oral
corticosteroids (Strength of recommendation D)
Patients with pruritus associated with Hodgkin lymphoma may benefit from BB-UVB for temporary relief from
itch (Strength of recommendation D)
Patients with pruritus associated with non-Hodgkin lymphoma may benefit from NB-UVB for temporary relief
from itch (Strength of recommendation D)
Generalized pruritus
(polycythaemia vera; PV)
Patients with generalized pruritus associated with PV may have their itch relieved with cytoreductive therapy,
aspirin, interferon-a, SSRIs, PUVA, UVB phototherapy, cimetidine or atenolol (Strength of recommendation D)
Patients with pruritus associated with PV may benefit from NB-UVB, BB-UVB, PUVA or PUVA in combination
with sunlight to relieve itch (although relapse is common after stopping treatment) (Strength of recommendation D)
Patients with aquagenic pruritus may benefit from NB-UVB, BB-UVB or combined UVA and UVB to relieve
itch (Strength of recommendation D)
Generalized pruritus (solid
cancers)
Paraneoplastic pruritus may be relieved with paroxetine, mirtazapine, granisetron or aprepitant (Strength of
recommendation D)
Generalized pruritus
(uraemia)
Ensure adequate dialysis, normalize calcium–phosphate balance, control parathyroid hormone to accepted
levels, correct any anaemia with erythropoietin and use simple emollients (for xerosis) in patients with
uraemic pruritus before using other treatment strategies (Strength of recommendation D)
No single topical/systemic treatment strategy is effective
• Consider capsaicin cream, topical calcipotriol or oral gabapentin (Strength of recommendation D)
• Sedative antihistamines long term may predispose to dementia and should be avoided, except in palliative
care (Strength of recommendation B)
• Cetirizine is not effective in uraemic pruritus (Strength of recommendation D)
BB-UVB is an effective treatment for many patients with uraemic pruritus (Strength of recommendation A)
Patients with uraemic pruritus should consider auricular acupressure or aromatherapy (Strength of recommendation D
(GPP))
Renal transplantation is the only definite treatment (Strength of recommendation D)
Generalized pruritus (liver
disease)
In hepatic pruritus consider rifampicin as first-line treatment (Strength of recommendation A)
In hepatic pruritus, do not use gabapentin (Strength of recommendation D (GPP))
In hepatic pruritus consider cholestyramine as second-line treatment (Strength of recommendation D (GPP))
In hepatic pruritus consider sertraline as third-line treatment before naltrexone or nalmefene (Strength of
recommendation D (GPP))
In hepatic pruritus consider as fifth-line treatment:
• systemic dronabinol, phenobarbitone, propofol or topical tacrolimus ointment (Strength of recommendation D)
• new specific agents based on blockade of bile acid transport, autotaxin and lysophosphatidic acid metabo-
lism (Strength of recommendation D)
• extracorporeal dialysis techniques, nasobiliary drainage and liver transplantation (Strength of recommendation D)
Patients with cholestatic pruritus may benefit from BB-UVB or combined UVA and UVB to relieve itch (Strength
of recommendation D)
Patients with hepatic pruritus may benefit from transcutaneous electrical nerve stimulation (Strength of
recommendation D)
Generalized pruritus
(neuropathy)
Patients with neuropathic pruritus should be referred to the relevant specialist for treatment (Strength of
recommendation D (GPP))
Generalized pruritus
(psychological and
emotional factors)
In distressed patients with chronic pruritus including likely psychogenic origin, consider psychosocial and
behavioural interventions including education on how to avoid trigger factors and apply treatments, lifestyle
interventions, relaxation techniques, cognitive restructuring and behaviour modification including habit
reversal training (Strength of recommendation D (GPP))
Patient support groups can be beneficial (Strength of recommendation D (GPP))
Referral to social workers, liaison psychiatry and psychologists may be helpful in individual cases (Strength of
recommendation D (GPP))
Patients with psychogenic pruritus (functional itch disorder) may benefit from NB-UVB (Strength of recommendation
D)
(continued)
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12.0 Recommended audit points
In the last 20 consecutive patients presenting with possible
GPWOR, were the following items recorded:
a. Ferritin
b. Full blood count
c. Urea and electrolytes
d. Liver function tests
e. Erythrocyte sedimentation rate (if available locally)
f. Chest X-ray
Healthcare professionals treating patients presenting with
possible GPUO at follow-up, where initial tests were negative,
may wish to audit the recording of the following additional
items, dependent on clinical findings. However, these do not
form part of our core recommended audit points:
Table 7 (continued)
Generalized pruritus
(infections and infestations)
In patients with generalized pruritus associated with HIV consider:
• indomethacin (Strength of recommendation D) or
• less toxic cyclooxygenase inhibitors (Strength of recommendation D (GPP))
Patients with HIV-associated pruritus may benefit from UVB phototherapy (Strength of recommendation D)
Patients with HIV-associated pruritus may benefit from oral PUVA (Strength of recommendation D)
In patients with generalized pruritus associated with HIV consider hypnosis to relieve itch (Strength of
recommendation D)
Generalized pruritus (drug
induced)
Naltrexone is effective in treating opioid-induced generalized pruritus without visible skin signs and is the first-
choice recommendation in this situation (if cessation of opioid therapy is impossible). Methylnaltrexone may
be an alternative (Strength of recommendation B)
In patients with opioid-induced generalized pruritus without visible skin signs consider methylnaltrexone,
ondansetron, droperidol, mirtazapine or gabapentin as alternative antipruritic agents (Strength of recommendation D
(GPP))
In patients with postoperative generalized pruritus without visible skin signs consider diclofenac 100 mg given
rectally (Strength of recommendation D (GPP))
In patients with chloroquine-induced generalized pruritus without visible skin signs consider prednisolone
10 mg, niacin 50 mg or a combination of prednisolone and niacin (Strength of recommendation D (GPP))
In patients with chloroquine-induced generalized pruritus without visible skin signs consider dapsone to relieve
itch (Strength of recommendation D (GPP))
Generalized pruritus of
unknown origin (GPUO)
Patients with GPUO should receive self-care advice and emollients (Strength of recommendation D (GPP))
Patients with GPUO should be referred to secondary care if there is diagnostic doubt, or if primary care
management does not relieve symptoms (Strength of recommendation D (GPP))
Patients with GPUO could be prescribed topical doxepin. Treatment should be limited to 8 days, 10% of body
surface area and 12 g daily (Strength of recommendation D (GPP))
Patients with GPUO may benefit from topical clobetasone butyrate or menthol (Strength of recommendation D)
Patients with GPUO should not use crotamiton cream (Strength of recommendation B)
Patients with GPUO should not use topical capsaicin or calamine lotion (Strength of recommendation D (GPP))
In GPUO, consider nonsedative antihistamines (H1 antagonists) such as fexofenadine 180 mg or loratadine
10 mg, or mildly sedative agents such as cetirizine 10 mg orally (Strength of recommendation D)
In GPUO, consider H1 and H2 antagonists in combination, for example fexofenadine and cimetidine (Strength of
recommendation D (GPP))
In GPUO, consider paroxetine, fluvoxamine, mirtazapine, naltrexone, butorphanol, gabapentin, pregabalin,
ondansetron or aprepitant orally (Strength of recommendation D)
Sedative antihistamines are recommended in GPUO only in the short-term or palliative setting, such as
hydroxyzine (Strength of recommendation D)
Patients with GPUO should consider acupuncture in combination with Chinese herbal remedies (Strength of
recommendation D)
Patients with GPUO should consider acupuncture as a second-line therapy (Strength of recommendation D)
Pruritus in elderly skin Patients with pruritus in elderly skin should initially receive emollients and topical steroids for a least 2 weeks
to exclude asteatotic eczema (Strength of recommendation D)
Moisturizers with high lipid content may be preferred in the elderly (Strength of recommendation D)
Patients with pruritus in elderly skin may benefit from gabapentin (Strength of recommendation D)
Patients with pruritus in elderly skin should not be prescribed sedative antihistamines (Strength of recommendation
C)
Patients with pruritus in elderly skin who have not responded to the initial treatment should be reassessed
(Strength of recommendation D)
Patients with pruritus in elderly skin should be referred to secondary care if there is diagnostic doubt, or if
primary care management does not relieve symptoms (Strength of recommendation D (GPP))
BB, broadband; NB, narrowband; PUVA, psoralen–ultraviolet A; SSRI, selective serotonin reuptake inhibitor; UV, ultraviolet.
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a. Investigation of potential blood loss
b. Serum bile acids
c. C-reactive protein
d. Lactate dehydrogenase
e. Thyroid function tests
f. Fasting glucose and glycated haemoglobin
g. Calcium and phosphate (and parathyroid hormone)
h. Vitamin D
i. Immunoglobulins
j. HIV and hepatitis A, B and C serology
k. Computed tomography scan of the neck, thorax, abdo-
men and pelvis
l. Magnetic resonance imaging of the brain and spinal cord
m. Nerve conduction studies
n. Malaria, strongyloidiasis and schistosomiasis screening
o. Skin biopsy
The audit recommendation of 20 cases per department is to
reduce variation in the results due to a single patient, and
allow benchmarking between different units. However,
departments unable to achieve this recommendation may
choose to audit all cases seen in the preceding 12 months. A
summary of the screening recommendations for GPWOR is
provided in Table 5.
13.0 Summary
See the full manuscript for details of the evidence. A summary
of investigations is provided in Table 6, with treatments sum-
marized in Table 7.
Pruritus or itch is a common and distressing symptom of
many dermatological, systemic and psychological disorders.
These guidelines explore the investigation and management of
generalized pruritus, whether due to problems with iron meta-
bolism, renal disease, hepatic cholestasis, malignancy, other
haematological disorders, endocrine disease, infection, neuro-
logical and psychological dysfunction or ageing, as well as pru-
ritus of unknown origin. It is important to exclude as many of
the secondary causes of pruritus as possible in any patient with
pruritus, because many of these secondary causes have specific
treatments, including the management of the underlying dis-
ease. The guidelines do not cover primary dermatological pru-
ritic conditions, nor do they cover pruritus in children or in
pregnancy (Table 1). They also do not cover the pathophysiol-
ogy of itch in great detail. Producing guidelines for the investi-
gation and management of pruritus is not straightforward.
Many publications reviewed are case reports, case series or open
trials with no long-term follow-up, so firm evidence-based con-
clusions are not always possible. Nevertheless, these guidelines
form a framework for the investigation and management of
generalized secondary pruritus and GPUO in adults.
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Appendix
Levels of evidence
Level of
evidencea Type of evidence
1++ High-quality meta-analyses, systematic reviews of
RCTs or RCTs with a very low risk of bias
(continued)
Appendix (continued)
1+ Well-conducted meta-analyses, systematic reviews
of RCTs, or RCTs with a low risk of bias
1 Meta-analyses, systematic reviews of RCTs, or RCTs
with a high risk of bias
2++ High-quality systematic reviews of case–control or
cohort studies. High-quality case–control or
cohort studies with a very low risk of
confounding, bias or chance and a high
probability that the relationship is causal
2+ Well-conducted case–control or cohort studies with
a low risk of confounding, bias or chance and a
moderate probability that the relationship is causal
2 Case–control or cohort studies with a high risk of
confounding, bias or chance and a significant risk
that the relationship is not causal
3 Nonanalytical studies (e.g. case reports, case series)
4 Expert opinion, formal consensus
RCT, randomized controlled trial. aStudies with a level of evi-
dence ‘’ should not be used as a basis for making a recom-
mendation.
Strength of recommendation
Class Evidence
A At least one meta-analysis, systematic review or
RCT rated as 1++, and directly applicable to the
target population, or
A systematic review of RCTs or a body of evidence
consisting principally of studies rated as 1+,
directly applicable to the target population and
demonstrating overall consistency of results, or
Evidence drawn from a NICE technology appraisal
B A body of evidence including studies rated as 2++,
directly applicable to the target population and
demonstrating overall consistency of results, or
Extrapolated evidence from studies rated as 1++ or
1+
C A body of evidence including studies rated as 2+,
directly applicable to the target population and
demonstrating overall consistency of results, or
Extrapolated evidence from studies rated as 2++
D Evidence level 3 or 4, or
Extrapolated evidence from studies rated as 2+, or
Formal consensus
D (GPP) A good practice point (GPP) is a recommendation
for best practice based on the experience of the
guidelines development group
RCT, randomized controlled trial; NICE, National Institute for
Health and Care Excellence.
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